Q3 2021 Investor Relations Results

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in registration Oncology Code Name AAA617 177 Lu-PSMA-617 ABL001 asciminib CTL019 KymriahⓇ INC424 Jakavi® Mechanism Radioligand therapy target PSMA BCR-ABL inhibitor CD19 CAR-T JAK1/2 inhibitor VDT482 tislelizumab PD1 inhibitor Indication(s) Metastatic castration-resistant prostate cancer, post-taxane Chronic myeloid leukemia, 3rd line r/r Follicular lymphoma Acute GVHD Chronic GVHD 2L ESCC Immunology, Hepatology, Dermatology Code AIN457 Name Cosentyx® 1. Approved in EU. Mechanism IL17A inhibitor Indication(s) Cosentyx 300mg auto-injector and pre-filled syringe Juvenile idiopathic arthritis References Innovation: Clinical trials Cardiovascular, Renal, Metabolism Code Name KJX839 Leqvio® Mechanism siRNA (regulation of LDL-C) Indication(s) Hyperlipidemia¹ 4 lead indication Lead indication Ophthalmology Code RTH258 BeovuⓇ Name Mechanism Indication(s) VEGF inhibitor Diabetic macular edema 56 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation